ReviewExploration of targeted anti-tumor therapy2024

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC.

Ken Akao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.